Market Overview:
Baculovirus Expression System, also known as BEVS, is a eukaryotic protein expression system that utilizes insect cells, infected with recombinant baculoviruses, for recombinant protein production. The system offers various advantages over other expression systems such as ability to perform post-translational modifications and ease of scale-up. It is used for expressing complex therapeutic proteins, vaccines, industrial enzymes and more.
Market Dynamics:
The growth of the baculovirus expression system market is driven by rising demand for insect cell line based protein expression systems over prokaryotic expression systems. Baculovirus expression offers significant advantages over bacterial and yeast expression such as ability to perform post-translational modifications like glycosylation, disulfide bond formation etc. which are critical for Activity and stability of some mammalian recombinant proteins and vaccines. Additionally, growing biologics market has increased the demand for biomanufacturing of complex proteins using advanced expression systems like BEVS. However, difficulty in virus amplification and scale-up is a challenge. Key players are focusing on developing innovative solutions to address these issues and enable large scale manufacturing. For instance, Thermo Fisher has developed EX-CELL Prime for insect cell culture process development platform to simplify optimization and scale-up of baculovirus insect cell culture processes.
The global Baculovirus Expression System Market Share is estimated to be valued at US$ 368.5 Mn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strength:
- Baculovirus has natural capabilities for highly accurate protein expression in insect cells making it a favorable option.
- It allows post-translational modifications similar to mammalian cells due to the insect cell's functioning which is important for human therapeutic production.
- Flexible platform allowing optimization of protein expression and scale up to industrial levels.
Weakness:
- Initial development of recombinant virus is time consuming requiring cloning and multiple rounds of amplification.
- Cost intensive due to requirement of specific insect cell lines, growth conditions as well as optimization requirement.
Opportunity:
- Growing biologics drug pipeline expansion indicating rising demand for scalable protein expression systems such as baculovirus.
- Emerging recombinant vaccines and therapies areas opening new areas of application.
Threats:
- Mammalian expression systems catching up in capabilities reducing advantages of baculovirus.
- Restriction in the size of heterologous genes that can be expressed limiting its application.
Key Takeaways
The global Baculovirus Expression System market is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing demand for efficient and reliable protein production system for biologics development.
Regional analysis:
North America is currently the dominant region for the baculovirus expression system market owing to presence of major players and availability of advanced research infrastructure. Asia Pacific is expected to exhibit fastest growth over the coming years driven by expanding R&D investments and improving laboratory capabilities in countries like China and India.
Key players operating in the Baculovirus Expression System are Thermo Fisher Scientific, Merck KGaA, Takara Bio, Agilent Technologies, Oxford Expression Technologies, Promega Corporation, Qiagen N.V., Bio-Rad Laboratories, New England Biolabs, Genscript Biotech Corporation, Syngene International Limited, Sartorius AG, Aragen Bioscience, Vivopure, Creative Biogene, Absolute Antibody, Rockland Immunochemicals, Protein Technologies Inc., Proteogenix, Virovek.
